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Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease, characterized 
by damage of lung epithelial cells, excessive deposition of extracellular matrix in the 
lung interstitium, and enhanced activation and proliferation of fibroblasts. S100a4, also 
termed FSP-1 (fibroblast-specific protein-1), was previously considered as a marker of 
fibroblasts but recent findings in renal and liver fibrosis indicated that M2 macrophages 
are an important cellular source of S100a4. Thus, we hypothesized that also in pulmo-
nary fibrosis, M2 macrophages produce and secrete S100a4, and that secreted S100a4 
induces the proliferation and activation of fibroblasts. To prove this hypothesis, we 
comprehensively characterized two established mouse models of lung fibrosis: infection 
of IFN-γR−/− mice with MHV-68 and intratracheal application of bleomycin to C57BL/6 
mice. We further provide in  vitro data using primary macrophages and fibroblasts to 
investigate the mechanism by which S100A4 exerts its effects. Finally, we inhibit S100a4 
in vivo in the bleomycin-induced lung fibrosis model by treatment with niclosamide. Our 
data suggest that S100a4 is produced and secreted by M2 polarized alveolar macro-
phages and enhances the proliferation and activation of lung fibroblasts. Inhibition of 
S100a4 might represent a potential therapeutic strategy for pulmonary fibrosis.
Keywords: s100a4, alternatively activated macrophages, lung fibrosis, fibroblast activation, fibroblast 
proliferation, M2 macrophages
inTrODUcTiOn
Idiopathic pulmonary fibrosis (IPF) is the most devastating interstitial lung disease (ILD), more 
deadly than most cancers, and death usually ensues 2–5  years after diagnosis due to respiratory 
failure (1, 2). It is characterized by damage of lung epithelial cells, excessive deposition of extracel-
lular matrix (ECM) in the lung interstitium, and enhanced activation and proliferation of fibroblasts, 
which ultimately leads to the distortion of normal lung architecture and loss of lung function (3). 
The underlying cause of IPF is not known (4) but recent studies imply that the interplay between 
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genetic factors [mutations and polymorphisms (SNPs)] and 
environmental factors ultimately lead to IPF (3). Recently, the 
FDA approved Ofev (nintedanib) and Esbriet (pirfenidone) for 
the treatment of IPF patients (5–7). However, these therapies do 
not work for all patients and new medicines with fewer adverse 
effects are highly desirable.
S100a4, also termed FSP-1 (fibroblast-specific protein-1), 
was previously considered as a marker of fibroblasts in different 
organs undergoing tissue remodeling including kidney, lung, 
liver, and heart (4, 8). Upregulation of S100a4 was observed in 
fibrotic lung tissue of patients and attributed to an increase in 
FSP-1 expressing fibroblasts (9) or to an increased expression 
by SFTPC (pulmonary-associated surfactant protein C) positive 
alveolar epithelial cells (10). However, in the mouse model of kid-
ney injury, S100a4 was found to be co-expressed with macrophage 
antigens Mac1, Mac2, and Mac3 as well as CD45 and CD68 (11). 
Similar findings were reported in renal and liver fibrosis (12–14). 
Thus, it is conceivable that also in lung fibrosis, macrophages 
could be an important cellular source of S100a4. Macrophages 
display various activation states, and the main activation phe-
notypes are classically activated (M1) and alternatively activated 
(M2) macrophages. The pro-inflammatory M1 macrophages are 
often associated with inflammation and tissue injury, whereas the 
anti-inflammatory M2 macrophages are associated with tissue 
repair and fibrosis by secreting pro-fibrotic factors (15, 16). Prior 
investigations have suggested that M2 alveolar macrophages 
(AMs), expressing high levels of Ym1/2, FIZZ1, and Arg1, play 
an important role in driving fibrogenesis (17).
Here, we hypothesized that also in pulmonary fibrosis, M2 
macrophages produce and secrete S100a4, and that the secreted 
S100a4 induces proliferation and activation of fibroblasts. To 
prove this hypothesis, we comprehensively characterized two 
established mouse models of lung fibrosis: infection of IFN-γR−/− 
mice with MHV-68 and intratracheal application of bleomycin 
to C57BL/6 mice. In addition, we provide in vitro data using pri-
mary macrophages and fibroblasts to investigate the mechanism 
by which S100a4 exerts its effect. Finally, we inhibit S100a4 in vivo 
with niclosamide in the bleomycin-induced lung fibrosis model.
Our data suggest that S100a4 is produced and secreted by M2 
polarized AMs and enhances the proliferation and activation of 
lung fibroblasts. Inhibition of S100a4 might represent a potential 
therapeutic strategy for pulmonary fibrosis.
MaTerials anD MeThODs
Preparation and Titration of MhV-68
Virus stocks were grown and quantified by plaque assay as previ-
ously described (18).
In Vivo experiments
C57BL/6 mice were purchased from Charles River Laboratories 
(Sulzfeld, Germany). IFN-γ-R−/− mice on C57BL/6 background 
were originally obtained from the Jackson Laboratory (Bar 
Harbor, ME, USA) and subsequently bred and propagated 
under SPF conditions at the Helmholtz Zentrum München. 
Mice were housed in individually ventilated cages during the 
MHV-68 infection period. Mice (8–12 weeks old) were infected 
intranasally (i.n.) with 1 × 105 plaque forming units of MHV-68 
diluted in PBS in a total volume of 30 µl. Prior to i.n. infection, 
mice were anesthetized with ketamine–xylazine or with medeto-
midine–midazolam–fentanyl. At the predetermined time points, 
mice were sacrificed by cervical dislocation and subsequently, 
bronchoalveolar lavage (BAL) was performed and lung tissues 
were quartered and processed for the following experiments: 
the left lobe was inflated and fixed in 10% buffered formalin for 
histological and immunohistochemical examination, and the 
remaining lobes were stored at −80°C and used for RNA isolation 
for qRT-PCR to determine gene expression or for preparation of 
whole lung tissue protein extracts and western blot analysis.
To induce pulmonary fibrosis, anesthetized mice (8–12 weeks 
old) were intratracheally instilled through a MicroSprayer 
Aerosolizer 20G INTROCAN (Penn Century, Wyndmoor, PA, 
USA) with 50  µl bleomycin (Sigma-Aldrich, Taufkirchen, 
Germany) in PBS (2 U/kg) or as control, with PBS alone. Mice were 
analyzed 14 days after bleomycin instillation. To test lung function, 
mice were anesthetized with ketamine/xylazine, intratracheally 
intubated through a small incision of the trachea and connected 
to the flexiVent system (Scireq, Montreal, Canada). Subsequently, 
mice were sacrificed and lung lobes were snap frozen and stored 
at −80°C before mRNA isolation and protein determination, 
and one lobe was filled with 4% paraformaldehyde for histology. 
Paraffin-embedded sections were stained with hematoxylin and 
eosin (H&E). Staining intensity was quantified by ImageJ.
All animal experiments were in compliance with the German 
Animal Welfare Act (German Federal Law §8 Abs. 1 TierSchG), 
and the protocols were approved by the local Animal Care and 
Use Committee (District Government of Upper Bavaria; permit 
number 124-08, 154-13, and 130-14).
Bronchoalveolar lavage
Immediately after euthanasia, BAL was conducted via the intro-
duction of a cannula into the trachea. A 1 ml aliquot of ice-cold 
Dulbecco’s phosphate buffered saline (DPBS) was flushed into 
the airway and gently aspirated via a syringe and the tracheal 
cannula. After the first BAL fluid (BALF) was collected, the BAL 
continued with seven times of 1.5  ml aliquots of PBS until an 
additional 7 ml of BALF was collected. The initial BALF was then 
centrifuged at 1,500 rpm for 5 min at 4°C, and the supernatant 
was collected and decanted into a new 1.5  ml microcentrifuge 
tube and stored at −80°C for biochemical measurements such as 
cytokine concentration. The remaining lavage fluid was pooled 
and centrifuged to remove the supernatant. The sedimented cells 
together with remnant cell pellets from the first lavage wash were 
subsequently resuspended in 1  ml PBS. Finally, the number of 
living cells was counted on a standard hemocytometer in the 
presence of 0.4% trypan blue (Sigma-Aldrich).
histopathology
After BAL harvesting, either the whole lung or the left lobe was 
inflated by 5 ml of 10% phosphate buffered formaldehyde solu-
tion (PFA) (AppliChem) and then gently removed and immersed 
in 10% PFA. An average of three mice per group at each experi-
mental time point was used for histopathological analysis. After 
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fixation for 24 h, dissected lung tissues were dehydrated through 
a series of solutions with increasing concentrations of ethanol and 
subsequently embedded in paraffin blocks. 3 µm thick adjacent 
sections were cut by the microtome (Carl Zeiss), so that all parts of 
the samples were represented on the slides. Prior to H&E staining, 
slides were baked at 60°C for 30 min. Subsequently, lung sections 
were prepared for histopathological staining by deparaffinization 
in xylene, and rehydration in a decreasing ethanol series (100, 90, 
80, and 70%, respectively) and distilled water. Slides were then 
stained with H&E according to the manufacturer’s protocols to 
determine histopathological changes and fibrosis. Briefly, lung 
sections were incubated in Mayer’s Hemalaun solution (Carl Roth) 
for 8 min, rinsed quickly in 0.3% acid–alcohol solution, washed, 
and then transferred into 0.5% eosin G solution (Carl Roth) for 
8 min. Sections were washed in tap water and dehydrated in a 
graded ethanol series and covered with Entellan (Millipore).
immunohistochemistry (ihc)
Serial lung tissue sections were processed as follows: slides were 
deparaffinized and incubated with 3% hydrogen peroxide (H2O2) 
(Spectrum Chemical Mfg. Corp.) in 100% methanol for 20 min 
at room temperature to quench endogenous peroxidase activity. 
Heat-induced antigen retrieval was performed with 0.05% citrate 
buffer pH 6.0 (Dako REAL Target Retrieval Solution) for 30 s at 
125°C and 10 s at 90°C. Subsequently, blocking was performed 
with Roden Block M buffer (Biocare Medical, Zytomed) for 1 h 
at room temperature to avoid non-specific antibody binding. To 
identify myofibroblasts or macrophages and products of alter-
natively activated macrophages, primary antibodies used were 
against α-smooth muscle actin (α-SMA), arginase I, and S100a4, 
according to the manufacturer’s instructions. The slides were 
incubated with corresponding secondary antibodies for 30 min 
at room temperature. Vulcan Fast Red Chromogen Kit (Biocare 
Medical, Zytomed) was used to visualize the positive stained cells 
and hematoxylin was used as counterstaining for nuclei. Isotype 
controls were routinely applied. The primary antibodies used 
for IHC staining were mouse anti-α-SMA monoclonal antibody 
(Sigma-Aldrich) diluted at 1:200 in antibody diluent (Zytomed 
Systems), rabbit anti-arginase I polyclonal antibody (Santa Cruz 
Biotechnology Inc.) at 1:200 dilution and rabbit anti-S100a4 
polyclonal antibody (Abcam) at 1:250 dilution. The secondary 
antibody applied was the rabbit-on-rodent alkaline phosphatase 
(AP) polymer (Biocare Medical, Zytomed) and mouse-on-mouse 
AP-polymer (Biocare Medical, Zytomed).
immunocytofluorescence staining
For immunocytofluorescence staining of arginase I and S100a4, 
primary AMs were seeded on a 24-well plate containing sterile 
round glass coverslips at a density of 5 × 105 cells/well and cul-
tured in the absence or presence of IL-4 (20 ng/ml). At 48 h after 
the initiation of stimulation, adherent cells were washed with 
precooled PBS and fixed with cold methanol for 10 min at room 
temperature. After washing three times in PBS for 5 min, cells 
were covered with blocking solution (1% BSA in PBS) for 30 min 
at room temperature, and then incubated with a mixture of 
mouse anti-S100a4 monoclonal antibody (Abcam) at 1:300 dilu-
tion and rabbit anti-arginase I polyclonal antibody (Santa Cruz 
Biotechnology Inc.) at 1:250 dilution for 1 h at room temperature. 
This was followed by an exposure to a mixture of secondary 
antibodies, a goat anti-mouse IgG Alexa Fluor® 488 secondary 
antibody (Thermo Scientific) and a goat anti-rabbit IgG Alexa 
Fluor® 633 secondary antibody (Thermo Scientific), at 1:500 
dilution, in the dark for 1  h. Stained cells were mounted with 
Mowiol which contains 4′,6-diamidino-2-phenylindole (DAPI) 
(Dako) to visualize the nuclei, and images were captured by a 
fluorescence microscope (LSM 700, Carl Zeiss). The appropriate 
irrelevant isotype-matched immunoglobulins were employed as 
negative controls.
For immunocytofluorescence staining of S100a4 and Mac3, 
lung sections were deparaffinized and hydrated using standard 
procedures. Sections were immersed into 3% H2O2 diluted in 
methanol for 20 min at room temperature to quench endogenous 
peroxidase. Antigen retrieval was performed using citrate buffer 
(pH6) and pressure cooker heating. Blocking was performed with 
1% BSA for 1 h at room temperature. Subsequently, sections were 
incubated overnight at 4°C with a mixture of rabbit anti-S100a4 
polyclonal antibody (Abcam) at 1:100 dilution and rat anti-mouse 
Mac3 monoclonal antibody (BD) at 1:50 dilution for 1 h at room 
temperature. After washing three times, immunofluorescence 
detection was performed using mixed secondary antibodies as 
follows: goat anti-rabbit Alexa Fluor® 633 (Thermo Scientific) 
and goat anti-rat Alexa Fluor® 488 (Thermo Scientific), both at 
1:500 dilution, in the dark for 1  h. Slides were mounted with 
fluorescence mounting medium containing DAPI (DAKO) to 
visualize the nuclei, and images were captured by a fluorescence 
microscope (LSM 700, Carl Zeiss).
Immunofluorescent stainings of S100A4 and CD163 in tis-
sue sections from human lungs were performed using a mouse 
monoclonal anti-CD163 antibody (Novus, NBP2-36494, 1:200) 
and a rabbit polyclonal anti-S100A4-antibody (abcam, ab41532, 
1:100), essentially as described previously (19). Human lung tis-
sue was obtained from the Comprehensive Pneumology Center 
cohort of the BioArchive CPC-M at the University Hospital 
Grosshadern of the Ludwig Maximilian University. Participants 
provided written informed consent to participate in this study, 
in accordance with approval by the local ethics committee of the 
LMU, Germany (Project 333-10, 455-12).
rna isolation From lung Tissue
Approximately, 20 mg frozen lung tissue was disrupted and com-
pletely homogenized in 350 µl TissueLyser LT buffer through the 
FastPrep-24 Lysator (MP Biomedicals). Total RNA was extracted 
and purified by utilizing the RNeasy Mini Kit (Qiagen) as per 
the manufacturer’s instruction. The concentration and purity of 
RNA samples were quantified by a Nanodrop ND-1000 spectro-
photometer (Thermo Scientific). RNA was stored at −80°C for 
quantitative real-time RT-PCR.
cDna synthesis
cDNA was generated from total RNA utilizing SuperScript RT III 
kit (Invitrogen) in a total volume of 20 µl. First-strand synthesis 
was performed in a total volume of 13.5 µl with 1 µg RNA, 1 µl 
10 mM dNTP (NEB), 1 µl random hexamers (50 µM), and RNase-
free distilled water. The mixture was incubated at 65°C for 5 min 
TaBle 1 | Primer sequences of genes of interest (GOI).
Target 
gene
Forward primer (5′–3′) reverse primer (5′–3′)
Actb TCCATCATGAAGTGTGACGT GAGCAATGATCTTGATCTTCAT
Arg1 GGAACCCAGAGAGAGCATGA TTTTTCCAGCAGACCAGCTT
Tnf CACCACGCTCTTCTGTCT GGCTACAGGCTTGTCACTC
Ribosomal 
protein l8
AAGGCGCGGGTTCTGTTTT GCTCTGTCCGCTTCTTGAATC
S100a4 TCAGCACTTCCTCTCTCTTGG AACTTGTCACCCTCTTTGCC
TaBle 2 | Antibodies utilized in western blot assays.
name Dilution company
Rabbit polyclonal anti-S100a4 antibody 1:1,000 Abcam, ab27957
Mouse monoclonal anti-S100a4 antibody 1:1,000 Abcam, ab93283
Rabbit polyclonal anti-arginase I antibody 1:1,000 Santa Cruz, sc-20150
Rabbit polyclonal anti-GAPDH antibody 1:1,000 Abcam, ab37168
Rabbit polyclonal anti-STAT6 antibody 1:1,000 Cell Signaling, #9362
Rabbit polyclonal anti-pSTAT6 antibody 1:1,000 Cell Signaling, #9361
Mouse monoclonal anti-β-actin-HRP-
conjugated antibody
1:50,000 Sigma-Aldrich, A3854
HRP-conjugated anti-mouse IgG 
secondary antibody
1:5,000 GE Health care, 9597364
HRP-conjugated anti-rabbit IgG 1:5,000 GE Health care, 356938
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and then chilled on ice immediately for at least 1 min. Thereafter, 
the following reagents were added to the RNA/hexamers mix-
ture: 4 µl 5 × first-strand buffer, 2 µl 0.1 mM DTT, and 0.5 µl of 
Superscript III (200 units). The obtained solution was incubated 
at 42°C for 1  h and reverse transcriptase was inactivated by 
incubating at 70°C for 10 min. cDNA was either stored at −20°C 
or subjected to quantitative real-time PCR analysis (diluted 1:10 
with H2O before use).
Quantitative real-Time Pcr
Quantitative real-time PCR (qPCR) was conducted using the 
ABI Prism 7300 real-time PCR System (Applied Biosystems, 
Life Technologies). Specific primers for the genes of interest 
were custom designed through the online PrimerBank database 
(https://pga.mgh.harvard.edu/primerbank/) and synthesized 
by Metabion (Martinsried, Germany). The housekeeping genes 
ribosomal protein l8 or β-actin were used to normalize for 
the input of loaded cDNA. 1  µl of cDNA was mixed with the 
appropriate 100 nmol/ml primers and 2 × SYBR Green Master 
Mix (Applied Biosystems, Life Technologies) in a total volume of 
25 µl. The sequences of primers are given in Table 1. Each qPCR 
reaction was carried out in a 96-well plate in duplicate with the 
following program: 95°C for 10 min for initial denaturation, 40 
cycles of amplification as follows: (1) denaturation at 95°C for 
15  s, (2) annealing and elongation at 60°C for 1  min. Melting 
curve analysis was also done with a continuous temperature 
increasing from 60°C to 95°C with a rate of 0.1°C/s to assess the 
specificity of the amplification process. Relative gene expression 
levels were calculated using the comparative Ct (ΔΔCt) method.
Protein isolation and Quantification
Total protein was extracted from lung tissue with precooled RIPA 
buffer (10  mM Tris, 150  mM NaCl, 5  mM EDTA, 1% sodium 
deoxycholate, 1% Triton X-100, 1% SDS) supplemented freshly 
with one tablet complete protease inhibitor cocktail (Roche) per 
10  ml. Samples were homogenized by the FastPrep-24 Lysator 
(MP Biomedicals) and placed on ice for 30 min with vigorous 
vortexing for every 10  min. All samples were centrifuged at 
14,000 rpm for 15 min at 4°C, and supernatants were collected 
and decanted in new microcentrifuge tubes and stored at −80°C. 
For isolation of whole cell extracts, cells were washed with pre-
cooled PBS and lysed with cold RIPA buffer for 30 min on ice. 
Cell debris was pelleted at 14,000 rpm for 15 min at 4°C and the 
supernatant was harvested and stored at −80°C. Protein concen-
trations were measured by Bradford assay with coomassie protein 
assay reagent (Thermo Scientific) according to manufacturer’s 
instructions with BSA (Thermo Scientific) as standards (0, 25, 
125, 250, 500, 750, 1,000, 1,500, and 2,000  µg/ml). Absorption 
at OD 595 was measured with a microplate absorbance reader 
(TECAN SUNRISE), and the BSA standard curve was applied to 
calculate concentrations of samples.
Western Blot analysis
Western blot was performed as follows: 25–50 µg total protein 
extract per sample was diluted in 4 × Laemmli Buffer (Biorad) 
supplemented with 5% β-mercaptoethanol and incubated for 
5 min at 95°C. Samples were resolved in 5–15% sodium dodecyl 
sulfate polyacrylamide gels for 90 min at 120V in tris-glycine run-
ning buffer in an electrophoresis tank (Bio-Rad). The pre-stained 
full-range rainbow molecular weight marker (GE Healthcare, 
Life Science) was used to indicate the protein size. Proteins were 
transferred to the nitrocellulose membrane (GE Healthcare, Life 
Science) in blotting buffer at 300 mA for 60 min in a Hoefer TE22 
Mini Tank (GE Healthcare, Life Science). The membrane was 
then soaked in 5% milk in TBS-T blocking buffer for 1 h at room 
temperature to prevent non-specific binding. Primary antibodies 
were diluted in 1% milk blocking buffer and incubated overnight 
at 4°C with agitation in a 50 ml falcon tube. After washing three 
times with TBS-T buffer, the membrane was incubated with the 
appropriate secondary antibody for 1  h at room temperature. 
The membrane was washed three times with TBS-T buffer, and 
the resulting signals were visualized and captured with Pierce 
ECL western blotting substrate (Thermo Scientific) and Bio-Rad 
imaging system (Thermo Scientific). If necessary, initial antibod-
ies could be stripped with Restore Stripping Solution (Thermo 
Scientific) for 8–15 min at room temperature. The nitrocellulose 
membrane was then washed with TBS-T, blocked with 5% milk 
in TBS-T, and reprobed with other antibodies as described above. 
The antibodies and dilutions employed are shown in Table 2.
Determination of s100a4 by elisa
Secreted S100a4 in cell culture supernatants or in BAL fluid was 
measured using a published sandwich ELISA (13). Briefly, 96-well 
NUNC MaxiSorp microplates (NUNCTM, Thermo Scientific) 
were coated with 1 µg/ml mouse anti-S100a4 monoclonal anti-
body (Abcam) at 4°C overnight. After blocking with assay buffer 
(PBS + 5% BSA), samples were added and incubated for 2 h at 
37°C, followed by incubation with 1 µg/ml rabbit polyclonal anti-
S100a4 antibody (Abcam) at room temperature with continuous 
shaking (700 rpm). Next, a secondary HRP-conjugated anti-rabbit 
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IgG (GE Healthcare, Life Science) was applied and proteins were 
detected by TMB substrate.
isolation of Mouse Primary resident aMs
To isolate lung AMs, C57BL/6 wild-type mice were anesthetized 
by injection of xylazine and ketamine intraperitoneally and 
killed by exsanguination. The trachea was exposed, cannulated, 
and the lungs were serially washed with 1 ml sterile PBS 10 times 
as described previously to harvest lavage fluid. Cell pellets were 
obtained by centrifugation at 1,500 rpm for 10 min at 4°C, and 
5 × 105 cells per well were seeded in 24-well plate in complete 
RPMI-1640 medium (Gibco) and incubated at 37°C and 5% CO2 
atmosphere. Cells were allowed to adhere for 60–90 min and then 
non-adherent cells were removed by washing twice with PBS.
isolation and cell culture of Mouse 
Primary lung Fibroblasts
C57BL/6 mice were euthanatized by exsanguination as described 
above. 15  ml cold PBS was perfused smoothly into the right 
heart ventricle until the lung got cleared of blood. The whole 
lung was removed and rinsed in pre-warmed DMEM/F-12 
(Gibco) medium supplemented with 1% penicillin/streptomycin 
(Gibco), 1% HEPES buffer (Gibco), and 15% FBS (PAA). The 
lung was diced into 1–2 mm pieces and digested with 0.1 mg/ml 
collagenase A (Roche) at 37°C for 2 h. Digested tissue was then 
minced using a 100  µm cell strainer (BD, Biosciences). After 
washing and centrifuging, cells were resuspended in complete 
DMEM/F-12 medium and incubated at 37°C with 5% CO2. 
The culture medium was changed every 2–3  days to remove 
unattached cells. After reaching 80–90% confluence, cells were 
detached by 0.25% trypsin (Gibco), split at 1:4 and applied to 
experiments at passages not higher than three.
Macrophage activation experiments
Isolated primary AMs were cultured in 24-well plates (5 ×  105 
cells/well) in RPMI-1640 medium (Gibco) supplemented with 
1% penicillin/streptomycin (Gibco) and 10% FBS (PAA) over-
night. The cells were stimulated with LPS (100  ng/ml, Sigma) 
and/or IFN-γ (20 ng/ml, Immuno Tools) to produce M1 mac-
rophages, or with IL-4 (20 ng/ml, Immuno Tools) to induce M2 
macrophage polarization. The application of a 72-h time course 
(6, 24, 48, and 72  h) and increasing doses of IL-4 (10, 20, 50, 
100, and 200  ng/ml) allowed for the accurate analysis of gene 
expression profiles and cytokine release without medium change 
or repeated administration of stimuli. Untreated macrophages 
incubated in culture medium served as controls. For the analysis 
of cytokines, supernatants were collected and subjected to ELISA 
for measurement of S100a4 as described above. Adherent cells 
were washed with ice-cold PBS and then harvested for total RNA 
or protein isolation.
cell Proliferation assay
Cell proliferation was evaluated after different treatments by uti-
lizing the cell proliferation kit II (XTT) (Roche) according to the 
manufacturer’s instructions. Briefly, primary lung fibroblast cells 
were plated into 96-well plates (3 ×  103 cells/well) in complete 
DMEM/F-12 medium (Gibco) and allowed to accommodate 
overnight before quiescing by replacing with serum-free medium 
for a further 12 h. Subsequently, cells were incubated in 2% FBS 
DMEM/F-12 medium with or without recombinant S100a4 
protein (2  µg/ml) or together with the anti-S100a4 antibody 
(3 µg/ml) (R&D Systems) for 72 h. Prior to harvesting, cells were 
treated with XTT labeling mixture for 4 h, and the absorbance 
was quantified at 450 nm with a reference wave length at 650 nm 
by using a microplate absorbance reader (TECAN SUNRISE). To 
verify whether the inhibition of S100a4 in M2 macrophages influ-
ences the pro-proliferative effect, M2 macrophage conditioned 
medium was incubated with S100a4 antibody (3 µg/ml) for 1 h 
at room temperature, and then applied on pre-starved primary 
lung fibroblast cells. Additionally, the conditioned medium from 
S100a4-siRNA transfected M2 macrophages was also applied on 
pre-starved cells. After 48 h, proliferation was evaluated by cell 
proliferation kit II (XTT) as mentioned above.
Wound healing assay
Cell migration was determined by wound healing assay. Initially, 
5 × 104 cells were seeded into a 24-well plate and allowed to adhere 
overnight until reaching about 70% confluence. Cell monolayers 
were inflicted by manually scraping with a 200 µl pipette tip and 
cell debris was removed by washing with PBS. Subsequently, cells 
were treated with the recombinant S100a4 protein (2 µg/ml) or 
that pre-incubated with the anti-S100a4 antibody (3  µg/ml) in 
culture medium supplemented with 2% FBS. Microphotographs 
were taken at 0 and 24 h after treatments with an Axiovert micro-
scope (Carl Zeiss). The wound areas were subsequently measured 
and each wound healing assay was conducted in triplicates. 
Finally, the cells were harvested for further analysis.
Transfection of Primary aMs With sirna
For specific knockdown of the S100a4 gene in primary AMs, a set 
of three siRNAs as well as a non-targeting negative control was 
purchased from Riboxx (Radebeul, Germany) (NM_011311.2). 
Prior to the experiments, the siRNA powder was reconstituted 
with RNase-free water in order to obtain the working solution 
with a final concentration of 600 nM. Primary AMs were pre-
pared as described above and seeded in 24-well plate at a density 
of 150,000 cells per well approximately 24 h before transfection. 
Cells were transfected in duplicates as follows: 3 µl riboxx®FECT 
transfection reagent diluted in 37  µl Opti-MEM (Gibco) were 
added to the 20  µl siRNA in 40  µl Opti-MEM. The reaction 
mixtures were incubated at room temperature for 15 min. In the 
meantime, the cell culture medium was aspirated and replaced 
with 500 µl fresh complete medium. Then, the mixture was added 
to each designed well to a final siRNA concentration of 20 nM/
well. After transfection for 72 h, supernatants were harvested for 
further experiments, and cells were harvested for RNA extraction 
and subsequent quantitative RT-PCR analysis.
cytotoxicity assay
The inhibitors of S100a4, calcimycin, and niclosamide 
(2′,5-dichloro-4′-nitrosalicylanilide), were purchased from 
Sigma and were solubilized in dimethyl sulfoxide (DMSO) for 
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in vitro experiments. To exclude adverse effects caused by DMSO, 
control cells were treated with the equal amount of solvent. 
Analysis of cell cytotoxicity was performed with the cell pro-
liferation kit II (XTT) (Roche) according to the manufacturer’s 
instructions. Briefly, cells were seeded at 1 × 104 cells per well in 
a 96-well plate and allowed to accommodate overnight. The cells 
were exposed to a series of different concentrations of calcimycin 
or niclosamide for 24  h. Subsequently, cells were treated with 
XTT labeling mixture for 4 h, and the absorbance was quantified 
at 450  nm with a reference wave length at 650  nm by using a 
microplate absorbance reader (TECAN SUNRISE). Cell viability 
was determined by dividing the absorbance ratio of drug-treated 
cells by the ratio obtained from untreated cells which was defined 
as 100% cell viability.
Pharmacologic inhibition of s100a4 
expression In Vivo
Mice were treated with niclosamide (Sigma) as described (20). 
Briefly, niclosamide (20 mg/kg) as suspension in 10% Cremophor 
EL (BASF, Ludwigshafen, Germany) and 0.9% NaCl solution was 
administered i.p. in a volume of 150  µl once daily from day 7 
to day 13 after bleomycin instillation. Control mice were treated 
with the appropriate volume of solvent solution (10% Cremophor 
EL and 0.9% NaCl).
statistical analysis
All statistics and calculations were conducted with GraphPad 
Prism version 6.0. Values are shown as mean ±  SD of at least 
three animals or three individual samples in each group if not 
otherwise indicated. The comparison of two groups was exam-
ined by unpaired Student’s t-test, and comparisons between 
several experimental groups were performed by analysis of 
variance. All significance tests were two-tailed and P values were 
expressed as follows: 0.05 > p > 0.01 as *; 0.01 > p > 0.001 as **; 
p < 0.001 as ***; p < 0.0001 as ****.
resUlTs
expression of s100a4 in Two Different 
animal Models of iPF
First, we analyzed the expression of S100a4 in the MHV-68 mouse 
model of IPF by qRT-PCR. S100a4 was highly expressed at day 
14 p.i. (acute inflammation phase) in both IFN-γR−/− and wild-
type (C57BL/6) mice. However, while it declined to baseline in 
wild-type mice, it remained high in IFN-γR−/− mice at day 45 p.i. 
(fibrotic phase) (Figure 1A). This could also be shown at the pro-
tein level (Figure 1B). Since it has been reported that S100a4 could 
also be secreted (21), an ELISA was performed to analyze S100a4 
protein in the BAL fluid from uninfected and MHV-68-infected 
IFN-γR−/− and wild-type mice. The level of soluble S100a4 protein 
was elevated during the pulmonary inflammation (day 20 p.i.) in 
both strains of mice, and remained high during the fibrotic phase 
(>day 60 p.i.) in IFN-γR−/− mice, while decreasing in wild-type 
mice (Figure 1C). Finally, the amount of S100a4 protein was also 
quantified in BAL fluid obtained from PBS- or bleomycin-treated 
C57BL/6 mice at 14 days after instillation, reflecting the fibrotic 
phase in this model (Figure 1D). An elevated expression level of 
S100a4 was observed in the bleomycin-treated mice. Consistent 
with previous results (22), these data indicate that a significantly 
increased level of S100a4 protein in the lung is a common phe-
nomenon during fibrogenesis, independent of the experimental 
mouse model.
ihc localizes s100a4 to aMs in Fibrotic 
Mouse lungs
In order to characterize the origin of S100a4 in the fibrotic lung 
tissue, immunohistochemical co-staining for S100a4 and the 
macrophage marker Mac3 was performed on lung sections of 
MHV-68 infected IFN-γR−/− mice and bleomycin-treated mice. 
As shown in Figures 2A,B, there was a strong co-staining of Mac3 
and S100a4, indicating that S100a4 is produced by macrophages 
present in the fibrotic lung. Since previous studies suggested that 
AMs driving the fibrotic process are activated by an alternative 
pathway (17), we hypothesized that S100a4 was secreted by 
alternatively activated macrophages. To confirm this, immu-
nohistochemical staining of S100a4 and Arg1 on consecutive 
lung sections was performed which demonstrated that S100a4 
positive cells matched with Arg1 positive cells (Figures S1A,B in 
Supplementary Material).
ihc localizes s100a4 to Macrophages  
in human lungs
Next, we wanted to test whether S100A4 is also expressed by 
macrophages in the human lung. As a proof of concept, immu-
nofluorescent co-staining for S100a4 and the macrophage marker 
CD163 was performed in lung sections. Macrophages expressing 
S100A4 were detected in lung sections of both, a control and an 
IPF patient (Figure 3). Consistent with these findings, S100A4 
was also found to be present in BAL fluids of both control and 
IPF patients (data not shown). Clearly, for a quantitative analysis, 
a lot more human samples need to be analyzed.
analysis of s100a4 expression in aMs 
isolated From control or Fibrotic Mice
To confirm that S100a4 is expressed by alternatively activated 
AMs, qRT-PCR was performed on freshly isolated AMs from 
uninfected and MHV-68-infected IFN-γR−/− mice when lung 
fibrosis was well established (days 45 and 90 p.i.). Significant 
increases of S100a4 (fivefold) and Arg1, as well as a decrease of 
TNF-α, a typical marker of classically activated macrophages, were 
found in AMs derived from virus-infected mice, when compared 
with macrophages derived from uninfected mice (Figure S2A in 
Supplementary Material). Furthermore, also AMs isolated from 
bleomycin-treated mice highly expressed S100a4 and Arg1 but only 
weakly expressed TNF-α (Figure S2B in Supplementary Material). 
These findings support the hypothesis that S100a4 originates from 
alternatively activated macrophages during lung fibrosis.
analysis of s100a4 gene expression  
in Polarized aMs
Alveolar macrophages can be polarized into M1 and M2 pheno-
types in vitro (23). Thus, we generated M1 and M2 macrophages, 
FigUre 1 | Analysis of S100a4 expression in two different mouse models of pulmonary fibrosis. (a) RNA was isolated from uninfected and from MHV-68-
infected IFN-γR−/− (ko) and C57BL/6 wild-type (wt) mice at days 14 and 45 after infection. S100a4 expression was analyzed by qRT-PCR, normalized to the 
expression of β-actin, and depicted as relative fold changes. Results are derived from three mice per group and shown as mean ± SD. (B) Lung homogenates 
from uninfected mice and MHV-68-infected mice at the indicated time points were subjected to western blot analysis for the S100a4 protein (three mice per 
group). Blots were either incubated with an anti-S100a4-antibody or an anti-GAPDH antibody as loading control. (c) S100a4 protein was measured in 
bronchoalveolar lavage (BAL) fluids from uninfected or MHV-68-infected IFN-γR−/− (ko) and C57BL/6 mice (wt) at days 20, 63, and 100 after infection. Each 
symbol represents a mouse. Results are derived from three mice per group and shown as mean ± SD. Unpaired t-test was performed for statistical analysis  
(* denotes p < 0.05; ** denotes p < 0.01; n.s. denotes non-significance). (D) Protein levels of S100a4 were measured in BAL fluid from PBS or bleomycin-treated 
C57BL/6 mice at 14 days after instillation. Each symbol represents a mouse. Results are derived from nine mice per group and shown as mean ± SD. Unpaired 
t-test was performed for statistical analysis (*** denotes p < 0.001).
FigUre 2 | Co-localization of S100a4 with Mac3+ macrophages in tissue sections from fibrotic mice. (a) MHV-68-infected IFN-γR−/− mice at 45 days after infection. 
(B) Bleomycin-treated C57BL/6 mice at 14 days after instillation. Green fluorescence: Mac3 antigen; red fluorescence: S100a4 antigen; blue fluorescence: 
diamidino-2-phenylindole-stained nuclei. In the merged image, yellow fluorescence indicates co-localization of S100a4 antigen and alveolar macrophages. All 
photomicrographs were taken at 200× magnification. Scale bar 50 µm.
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FigUre 3 | S100A4 is expressed by CD163+ macrophages in tissue sections from human lungs. Representative immunofluorescent stainings of paraffin sections 
from donor (left-hand panels) and idiopathic pulmonary fibrosis (IPF) tissue (right-hand panels) including higher magnification inserts in the bottom row. S100A4 is 
shown in red, the macrophage marker CD163 in green, and diamidino-2-phenylindole (DAPI) in blue. Scale bar 50 µm.
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isolated total RNA, and performed qRT-PCR. The expression 
profile of S100a4 in polarized AMs matched the expression pat-
tern of Arg1. Both S100a4 and Arg1 were significantly elevated in 
M2 polarized AMs, when compared to the control M0 and M1 
polarized macrophages (Figure S3 in Supplementary Material). 
Following the mRNA profile, we also investigated protein expres-
sion of S100a4 during alveolar macrophage polarization. Cells 
were treated with LPS or IFNγ and IL-4 or IL-13 for various times. 
The effects of IL-13 on activation of macrophages are similar to 
IL-4 (24), and both of them can induce the phosphorylation of 
STAT6 (25). Thus, phosphorylated STAT6 is used as a marker 
of M2 polarization. As expected, S100a4 protein was dectected 
after IL-4 and IL-13 induced M2 polarization but not in M0 or 
M1 polarized macrophages (Figures S4A,B in Supplementary 
Material). To confirm that S100a4 is secreted by M2 polarized 
macrophages, we performed ELISA tests on supernatants of IL-4-
treated primary AMs from both IFN-γR−/− and wild-type mice. 
The soluble S100a4 in the supernatant from IL-4-treated mac-
rophages increased five to seven times compared with untreated 
cells (Figure S4C in Supplementary Material). Significantly, 
higher S100a4 production was found in M2 polarized AMs from 
IFN-γR−/− mice compared to wild-type mice, which indicated 
that macrophages from IFN-γR−/− mice possess an enhanced 
capacity for IL-4 stimulation, which is also consistent with our 
in vivo data (Figures 1A–C). Double immunofluorescence stain-
ing for S100a4 and Arg1 on M2-polarized macrophages showed 
co-localization of S100a4 and Arg1 (Figure S5 in Supplementary 
Material). Hence, the expression of S100a4 was substantiated by 
qRT-PCR, western blot, ELISA, and double immunofluorescence 
staining analysis, providing strong evidence that S100a4 is pro-
duced by M2 polarized AMs.
effect of s100a4 on the activation, 
Proliferation, and Migration of Primary 
lung Fibroblasts
M2 macrophages secrete Th2 cytokines, thereby promoting fibro-
genesis via enhancing collagen deposition, angiogenesis, and 
fibroproliferation (26). Thus, S100a4 might serve as a cytokine-
like factor indirectly promoting the pathogenesis of lung fibrosis. 
To investigate the influence of extracellular S100a4 on lung 
fibroblasts, primary mouse lung fibroblasts isolated from wild-
type mice were treated with recombinant S100a4 for 24  h. As 
shown in Figure  4A, 0.1–3  µg/ml S100a4-induced significant 
expression of alpha-smooth muscle actin (α-SMA, a marker for 
myofibroblasts) in a concentration-dependent manner. When 
primary mouse lung fibroblasts were cultured in the presence 
of recombinant S100a4 protein, expression levels of α-SMA 
and collagen I were elevated 24 and 48 h after exposure, when 
compared to control cells (Figure 4B). This effect was blocked 
by neutralization of S100a4 with the specific antibody. These 
results indicate that S100a4 promotes activation of lung fibro-
blasts. Similarly, 72  h after stimulation, S100a4 significantly 
accelerated proliferation of lung fibroblasts when compared to 
control or antibody treated cells (Figure 5A). In fibrotic diseases, 
fibroblasts migrate to the wound site and participate in the con-
struction of scar tissue. Hence, we performed a wound healing 
assay to investigate the influence of S100a4 on the migration of 
lung fibroblasts. Enhanced cell migration ability was observed 
in pulmonary fibroblasts after treatment with recombinant 
S100a4 which was significantly reduced by blockade with S100a4 
neutralizing antibody (Figures 5B,C).
reduction of s100a4 secretion by M2 
Macrophages Diminishes its Proliferative 
effect on Primary lung Fibroblasts
In order to investigate the role of endogenous S100a4 produced 
by M2 macrophages on primary lung fibroblasts with respect to 
proliferation and myofibroblast differentiation, AMs were isolated 
and ex vivo polarized into M2 macrophages by IL-4 treatment 
in the presence of anti-S100a4 siRNA or control siRNA. 72  h 
later, the supernatant was harvested and transferred to primary 
lung fibroblasts. Subsequently, the proliferation of the primary 
lung fibroblasts was analyzed (Figure S6A in Supplementary 
Material). S100a4 mRNA was efficiently downregulated by 
FigUre 4 | S100a4 promotes activation of lung fibroblasts. (a) Primary lung fibroblasts were treated with various concentrations of recombinant S100a4 (0–3 µg/
ml) for 24 h, and expression of α-SMA was assessed by qRT-PCR. Results are mean ± SD of duplicate samples from one experiment. (B) Cells were treated with 
2 µg/ml recombinant S100a4 or with recombinant S100a4 in the presence of a S100a4 neutralizing antibody for 24 and 48 h, respectively. Cells were harvested and 
analyzed for expression of α-SMA and collagen I by western blot. S100a4 neutralization eliminated activation of lung fibroblasts. Results are representative of three 
independent experiments with similar results.
FigUre 5 | S100a4 accelerates lung fibroblast proliferation and migration. (a) Primary lung fibroblasts were treated with 2 µg/ml recombinant S100a4 or with 
recombinant S100a4 in the presence of a S100a4 neutralizing antibody or with antibody alone for 72 h. Cell proliferation was analyzed using the XTT kit. Results are 
representative of three independent experiments with similar results. Shown are mean ± SD of five replicates from one experiment. Unpaired t-test was performed 
for statistical analysis (**** denotes p < 0.0001). (B) Direct migration of primary lung fibroblasts in the presence of 2 µg/ml recombinant S100a4 or recombinant 
S100a4 in the presence of the S100a4 neutralizing antibody was analyzed by wound healing assay. Wound closure was determined 24 h after scratching. 
Representative phase-contrast pictures of the cells at 0 (immediately after the scratch) and 24 h after the scratch are shown. The assay was performed three times: 
one representative experiment is presented. (c) For quantification, the wound area was measured using ImageJ and normalized to control at 0 h. Results are 
representative of three independent experiments with similar results. Shown are mean ± SD of triplicate samples from one experiment. The effect of stimulation by 
S100a4 was statistically significant in comparison to the control sample, as evaluated by the unpaired t-test (** denotes p < 0.01; *** denotes p < 0.001).
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transient transfection with S100a4 specific siRNAs, when com-
pared to transfection with control siRNA or to un-transfected 
M2 macrophages (Figure S6B in Supplementary Material). 
Furthermore, the amount of S100a4 protein in the supernatants 
of M2 macrophages was also efficiently downregulated (Figure 
S6C in Supplementary Material). Yet, inhibition of S100a4 during 
FigUre 6 | Effect of conditioned medium on lung fibroblast proliferation. 
Primary lung fibroblasts were treated with conditioned medium (C.M.) from 
M0, M2, and M2 macrophages transfected with scrambled or S100a4-
specific siRNA. In addition, specific S100a4 antibody or isotype control rabbit 
serum pre-treated M2 conditioned medium were used to stimulate lung 
fibroblasts. Cell proliferation was analyzed by using XTT kit after 48 h of 
treatments. Results are representative of two independent experiments with 
similar results. Shown are mean ± SD of five replicates from one experiment. 
Unpaired t-test was performed for statistical analysis (** denotes p < 0.01; 
****denotes p < 0.0001).
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M2 polarization did not interfere with the expression of Arg1, 
which suggests that S100a4 is not involved in the polarization 
of macrophages (Figure S6D in Supplementary Material). To 
investigate the role of S100a4 produced by M2 macrophages on 
primary lung fibroblast proliferation, conditioned supernatants 
from control M2 macrophages or anti-S100a4 siRNA-transfected 
M2 macrophages were transferred to primary lung fibroblast 
cultures, and the effect on proliferation was evaluated after 24 h. 
Conditioned medium from anti-S100a4 siRNA-transfected 
M2 macrophages caused significantly less proliferation of lung 
fibroblasts when compared to conditioned medium from con-
trol macrophages (Figure  6). In addition, S100a4 neutralizing 
antibody also reduced supernatant-driven proliferation, while 
addition of control rabbit serum had no effect (Figure 6). These 
observations suggested that S100a4 is one of the soluble factors 
produced by M2 polarized AMs which are able to enhance the 
proliferation of fibroblasts.
Pharmacologic inhibition of s100a4 
expression
Previous studies reported that calcimycin and niclosamide, as 
transcriptional inhibitors of S100a4, can block S100a4 expres-
sion in colon cancer cells, thereby affecting metastasis (20, 27). 
To analyze the inhibitory potential of calcimycin and niclosamide 
on the expression of S100a4 in M2-polarized primary AMs, calci-
mycin, and niclosamide were applied to primary AMs during M2 
polarization. Both compounds significantly reduced the S100a4 
mRNA expression level but not the Arg1 expression (Figures 
S7A,B in Supplementary Material). Given the ability of calci-
mycin and niclosamide to inhibit S100a4 expression in primary 
AMs in vitro, we asked whether inhibition of S100a4 in vivo could 
attenuate the development of pulmonary fibrosis. We selected 
niclosamide, since it had been successfully applied before in 
mouse models of colon cancer (20). To induce lung fibrosis, mice 
were intratracheally treated with bleomycin, or as a control, with 
PBS. From day 7 after bleomycin instillation on, mice were treated 
daily with niclosamide or vehicle and monitored daily for signs 
of disease, and mice that appeared moribund were sacrificed. 
Treatment with niclosamide significantly improved the survival 
of bleomycin-instilled mice (Figure 7A). While in the group of 
vehicle-treated mice, 6 out of 8 animals had to be sacrificed until 
day 14, only 2 animals had to be sacrificed in the niclosamide-
treated group. At day 14 after bleomycin instillation, the surviving 
mice were analyzed for S100a4 protein concentrations in the BAL 
fluids (Figure 7B). Consistent with our in vitro data, treatment 
with niclosamide reduced the levels of S100a4, when compared to 
vehicle treatment. However, the reduction did not reach statisti-
cal significance (p = 0.103), since it was observed in only 4 out of 
6 niclosamide-treated mice. Obviously, in two mice, a reduction 
of S100a4 was not achieved by treatment with niclosamide. When 
we stratified the mice according to the S100a4 concentration in 
the BAL fluid (S100a4low versus S100a4high), the difference 
between the vehicle-treated mice and the niclosamide-treated, 
S100a4low mice became highly significant (Figure 7C). Second, 
lung function was determined (Figure 7D). Consistent with the 
BAL S100a4 concentrations, treatment of bleomycin-instilled 
mice with niclosamide significantly improved lung compliance 
in the four S100a4low mice but not in the two S100a4high mice, 
when compared to vehicle-treated mice, restoring lung function 
close to the level observed in mice instilled with PBS. Finally, lung 
tissue was histologically analyzed by staining with hematoxylin/
eosin (Figure 8). As expected, no fibrosis was observed in con-
trol animals instilled with PBS, while strong evidence of fibrosis 
was noted in bleomycin-instilled animals treated with vehicle. 
Importantly, in bleomycin-instilled animals treated with niclosa-
mide, fibrosis was significantly attenuated in the four S100a4low 
mice but not in the two S100a4high mice.
DiscUssiOn
S100a4 was originally considered as a protein specifically 
expressed by fibroblasts. However, it has recently been shown 
that in IPF, S100a4 confers fibrogenicity also on mesenchymal 
progenitor cells (28), and that its expression in kidney and liver 
fibrosis coincides with the presence of macrophages. Since 
lung fibrosis is also driven by monocyte-derived macrophages 
(29), we hypothesized that macrophage-derived S100a4 might 
also contribute to the development of lung fibrosis. Here, we 
present data consistent with this hypothesis: when compared 
to healthy controls, IHC staining of sections of fibrotic lungs of 
mice showed increased numbers of S100a4-positive cells which 
co-localized with Arg1 expressing M2 AMs. S100a4 was found 
to be strongly upregulated in BALF of two independent murine 
models of pulmonary fibrosis. Consistent with the findings in 
mice, we also observed macrophages expressing S100A4 in 
lung sections of both a control and an IPF patient, and detected 
S100A4 in BAL fluids of both control and IPF patients. However, 
FigUre 7 | Niclosamide treatment in vivo. (a) Treatment with niclosamide improves survival of bleomycin-instilled mice. Mice were intratracheally treated with 
bleomycin, or as a control, with PBS. Beginning at day 7 after bleomycin instillation, mice were treated once daily with niclosamide (20 mg/kg) or vehicle. Mice were 
monitored daily for signs of disease, and any mice that appeared moribund were sacrificed. Treatment with niclosamide significantly improved the survival of 
bleomycin-instilled mice [*p = 0.031; Log-rank (Mantel–Cox) test]. Numbers in brackets indicate the total number of mice per group. (B,c) Treatment with 
niclosamide reduces S100a4 protein in the BAL fluid. The surviving mice depicted in panel (a) were subjected to BAL. The protein concentration of S100a4 in the 
BAL fluids was determined by ELISA. Each symbol represents a mouse. Results are shown as mean ± SD. Unpaired t-test was performed for statistical analysis 
(***p < 0.001; ****p < 0.0001). (D) Treatment with niclosamide improves lung function. The surviving mice depicted in panel (a) were subjected to a lung function 
test, and lung compliance was determined. Each symbol represents a mouse. Results are shown as mean ± SD. Unpaired t-test was performed for statistical 
analysis (*p < 0.05; **p < 0.01).
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we did not observe a difference between the two groups which 
may be due to the very limited number of samples studied so 
far. S100A4 was also found to be significantly increased in BAL 
fluids of COPD patients when compared to controls (30). On 
the other hand, a recent deep proteome profiling of tissue from 
human end stage ILD cases and healthy donor controls did not 
reveal differences in S100A4 protein levels (31). Thus, the role 
of macrophage-derived S100A4 in human lung fibrosis requires 
further investigations.
Our in  vitro studies demonstrated induction of S100a4 in 
M2-polarized murine primary AMs. S100a4 has both intracel-
lular as well as extracellular functions. Intracellular S100a4 
plays a dynamic role in numerous biological processes that are 
fundamental for cell homeostasis and differentiation (32). When 
secreted extracellularly, S100a4 serves as a cytokine that regu-
lates cell survival, migration, and differentiation and remodeling 
of ECM in cancer cells (32). Here, we determined the effects of 
extracellular S100a4 on pulmonary fibroblasts, which are the 
most prominent cellular players in the production of ECM, such 
as collagen and fibronectin, in the lung. We provided the following 
lines of evidence to demonstrate a profibrotic role of extracellular 
S100a4 in pulmonary fibrosis: (i) recombinant S100a4 protein had 
cell growth-promoting properties on lung fibroblasts. (ii) S100a4 
induced the expression of the mesenchymal markers α-SMA 
FigUre 8 | Treatment with niclosamide reduces the histological evidence of fibrosis. Lung tissue of the surviving mice depicted in Figure 7 was subjected to 
histological analysis. (a) Representative images of H/E-stained lung sections. (B) Quantitative analysis of all HE-stained sections. Each symbol represents a mouse. 
For each mouse, 3–5 sections were scanned using ImageJ. Results are shown as mean ± SD. Unpaired t-test was performed for statistical analysis (* denotes 
p < 0.05).
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and collagen 1, indicating that S100a4 promoted lung fibroblasts 
transition to myofibroblasts which, in turn, synthesized elevated 
levels of ECM components. Blockage of S100a4 with neutralizing 
antibodies reduced those effects. Our results are in agreement 
with the study by Lin et al., reporting an S100a4-induced activa-
tion of hepatic stellate cells to promote liver fibrosis (13).
Since the discovery of S100a4, several studies have proven a 
central role of S100a4 in metastasis formation or liver fibrogen-
esis. Hence, targeting S100a4 expression provides a promising 
strategy for rational therapies. Previous research has shown that 
inhibition of S100a4 expression in cancer cell lines suppressed 
cell invasion in vitro (33). In vivo treatment with anti-S100a4-
shRNA or S100a4-neutralizing antibody in fibrotic mice reduced 
accumulation of myofibroblasts, suppressed deposition of 
collagen, and, therefore, ameliorated the development of liver 
fibrosis (13). Furthermore, Sack and colleagues performed 
high-throughput screening of 1,280 pharmacologically active 
compounds to identify a transcription inhibitor of S100a4 using 
a human colon cancer cell line. Niclosamide and calcimycin 
were identified as potential candidates (20, 27). Niclosamide 
[5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide] 
is an FDA-approved anti-helminthic compound used both 
in humans and animals for the treatment of tapeworm infec-
tion since more than 40  years (34). It has been reported that 
niclosamide inhibited the constitutively active WNT/CTNNB1 
signaling pathway by hindering the formation of CTNNB1/TCF 
transcription activating complex at the S100a4 promoter, thus 
inhibiting the expression of S100a4 at the transcriptional level. 
In vitro treatment with niclosamide inhibited S100a4-induced 
migration and proliferation of human colon cancer cells. 
Besides, niclosamide treatment also attenuated S100a4-induced 
metastasis formation in  vivo (20). Calcimycin is one of few 
natural ionophore antibiotics that specifically transport divalent 
cations such as calcium and magnesium (35). It has been shown 
that calcimycin treatment inhibited the constitutively active 
WNT/β-catenin pathway, thus hindering S100a4 expression and 
attenuating the S100a4-induced cell migration and invasion both 
in vitro and in vivo. Moreover, calcimycin has been reported to 
reduce the expression of S100a4 at the mRNA level in human 
monocytes and lymphocytes (36). In line with these findings, 
both niclosamide and calcimycin were, in our study, able to abro-
gate the expression of S100a4 during M2 polarization without 
influencing the polarization of macrophages. Most importantly, 
niclosamide treatment of bleomycin-instilled mice significantly 
reduced both the amount of S100a4 in the BAL fluid and the 
development of lung fibrosis in 50% of the treated mice. The rea-
son why the beneficial effect of niclosamide was observed only in 
50% of the treated mice is currently not known. Since it is known 
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that the response to intratracheal bleomycin instillation can be 
heterogeneous, we cannot completely rule out the possibility that 
some mice received less bleomycin than others. However, both 
groups receiving bleomycin displayed a significantly reduced 
body weight at day 7 after bleomycin instillation (i.e., at the 
beginning of the niclosamide treatment), when compared to 
the PBS control groups, suggesting a comparable response to 
bleomycin (Figure S8 in Supplementary Material). In contrast, 
the weight loss between the two bleomycin groups was not 
significantly different, albeit it appeared less pronounced in the 
niclosamide group. Therefore, we speculate that the niclosamide 
treatment regimen we have applied was sufficient to ameliorate 
fibrosis development in response to a certain effective dose of 
bleomycin but not beyond that. Still, our results suggest that 
S100a4 warrants further investigation as a therapeutic target in 
pulmonary fibrosis. Treatment with niclosamide clearly reduced 
the levels of S100a4 in vivo (Figure 7C), yet, it should be noted 
that niclosamide is not specific for S100a4. In pulmonary fibrosis, 
this unspecificity may even be favorable, since niclosamide co-
inhibits several pathways (e.g., STAT3, AKT, and Wnt/β-catenin) 
which have been shown to contribute to fibrosis development. 
Consistent with that are recent findings demonstrating preven-
tion of systemic sclerosis by niclosamide treatment in a reactive 
oxygen species-induced mouse model (37). It should be noted, 
however, that so far all data including ours are derived from well 
established mouse models, and that the relevance for human 
fibrosis still remains to be shown.
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